The Somerset-based augmented consumer platform for the life sciences industry said it is transforming how top global pharma companies use analytics to increase the top line and reduce the bottom line.
WhizAI said it is exclusive to the life sciences industry. The artificial intelligence technology is pretrained in the language, domain and analytics to deliver timely, specific insights.
It is able to help large and midsized pharma:
- Reduce total cost of ownership by approximately 50% while modernizing and streamlining legacy analytics systems through intelligent automation;
- Empower business users in sales, commercial ops, marketing, research & development and supply chain through contextual, actionable insights without monthlong wait times and complex software that needs high-level technical skills; and
- Improve business outcomes by identifying key opportunities, eliminating operational inefficiencies and streamlining the analytics ecosystem.
“We are fundamentally changing the way analytics is done in life sciences by helping our customers keep pace with large scale data, on-demand analytics and timely insights,” Rohit Vashisht, co-founder and CEO of WhizAI, said. “The future of analytics is augmented via AI to enable everyone to be insights-driven. We are delighted that our investors share this vision and support us to fulfill our mission.”
WhizAI plans to use the capital to grow its industry footprint by expanding its team across the globe and investing in sales and marketing so that more companies can get the fast, easy and contextual insights necessary to compete.